Clinical Trials Logo

Filter by:
NCT ID: NCT06320041 Not yet recruiting - Postoperative Pain Clinical Trials

Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial] is to further explore the effectiveness and safety of oxelidine in the treatment of moderate to severe acute pain after orthopedic surgery. The main question it aims to answer is: Pain management after orthopaedic surgery provides more effective and safe drug options, provides new options for clinical treatment, and provides a scientific basis for clinical practice. Participants will be asked to pain score in the different time, treatments they'll be given and use optimal drug. Researchers will compare analgesic effect of oxelidine of different dose.

NCT ID: NCT06320249 Not yet recruiting - Clinical trials for Cervical Radiculopathy

Rotation-traction Manipulation of Different Treatment Frequency in Cervical Radiculopathy

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The evidence for different frequencies of rotation-traction manipulation treatment in cervical radiculopathy is insufficient. This study determined whether 3 sessions per week of rotation-traction manipulation treatment are superior to 1 session per week for symptomatic outcomes in cervical radiculopathy based on a multicenter randomized controlled trial.

NCT ID: NCT06321237 Not yet recruiting - Clinical trials for Irritable Bowel Syndrome

Influence of Ear Vagus Nerve Stimulator on Patients With IBS

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Irritable bowel syndrome (IBS) is a very common functional digestive disorder characterized by chronic abdominal pain and altered bowel habits in the absence of biological or structural abnormalities. In the field of IBS, effective drug treatments are very limited, and patients are urgently looking for alternatives, including probiotics, hypnotherapy, osteopathy, dietary changes, and fecal microbiota transplants. In recent years, with the continuous elucidation of vagus nerve mechanisms, IBS patients are increasingly interested in bioelectrical regulation, and these patients are often skeptical of traditional drug treatment and believe that drugs are prone to side effects. For several reasons, vagus nerve stimulation (VNS) may be a promising option for improving IBS symptoms. In this experiment, the portable ear nail stimulator produced by Ruishen Medical can accurately stimulate the ear nail, transdermal stimulation of the ear vagus nerve, and give full play to its therapeutic effect. Therefore, the purpose of this clinical trial is to use ear nail stimulator in patients with IBS to explore whether it has therapeutic effects on patients with IBS. To explore the influence of tVNS therapy on irritable bowel syndrome compared with drug therapy, it is hoped that the use of TVNS therapy can reduce the use of related drugs, or even replace drugs. This study intends to recruit a group of patients with irritable bowel syndrome to use the portable ear nail stimulator, (1) to observe whether the symptoms of irritable bowel syndrome patients are improved; (2) To analyze the changes of intestinal microbes in patients with IBS; (3) Verify whether the level of intestinal inflammation is reduced and discover metabolic markers in the intestine.

NCT ID: NCT06321510 Not yet recruiting - Lung Cancer Clinical Trials

A Study to Learn About Dacomitinib in Patients With Non-small Cell Lung Cancer.

Start date: April 1, 2024
Phase:
Study type: Observational

The purpose of this study is to learn about dacomitinib for the possible treatment of lung cancer. This study is seeking participants who: - have lung cancer that could not be controlled. - have a type of gene called epidermoid growth factor receptor. A gene is a part of your DNA that has instructions for making things your body needs to work. - have received dacomitinib for their lung cancer. All participants in this study had received dacomitinib. Dacomitinib is a tablet that is taken by mouth at home. They continued to take dacomitnib until their cancer was no longer responding. The study will look at the experiences of people receiving the study medicine. This will help to see if the study medicine is safe and effective.

NCT ID: NCT06321965 Not yet recruiting - Clinical trials for Spinal Muscular Atrophy

Characterization of New Phenotypes of Patients With Spinal Muscular Atrophy Treated With SMN Restoring Therapy

PHENO SMART
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

With the advent of new treatments for ASI, new phenotypes are emerging. The investigators propose to describe these new phenotypes by prospectively following children with ASI of all types treated with TRS and aged under 16 for 2 years. The investigators also propose to evaluate potential assessment tools to determine whether they are relevant for monitoring this population, either routinely or for future clinical trials. The investigators also aim to collect the total costs associated with ASI in order to propose a first prospective medico-economic study in France.

NCT ID: NCT06322563 Not yet recruiting - Clinical trials for Advanced/Metastatic Colorectal Cancer

Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This is a phase II clinical study to evaluate the safety, tolerability and preliminary antitumor activity of LTC004 in combination with regorafenib in patients with mCRC. A safety introductory trial was conducted to receive LTC004 in combination with regorafenib before starting the formal trial. After completing a 28-day safety assessment, safety will be confirmed before entering the formal trial phase. Further evaluation of the safety and efficacy of LTC004 in combination with regorafenib in the treatment of mCRC

NCT ID: NCT06322810 Not yet recruiting - Analgesia Clinical Trials

ESP Versus PIFB for Analgesia in Open Cardiac Surgery: a Randomized Control Trial

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

This clinical trial compares analgesia efficiency and recovery outcomes between two different fascial plane block techniques (ESPB vs.PIFB) in cardiac surgery patients participant population/health conditions]. The main questions it aims to answer are: - Does ESPB provide superior analgesia than PIFB - Do patients who receive ESPB have better recovery outcomes

NCT ID: NCT06323148 Not yet recruiting - Lung Cancer Clinical Trials

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

This study plans to conduct ctDNA testing on EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients after radical surgery (R0 resection). Patients with positive ctDNA testing will receive standard treatment according to clinical guidelines, while patients with negative ctDNA testing will be assessed based on comprehensive clinical and pathological characteristics. After receiving or not receiving standard adjuvant chemotherapy, patients will be randomly assigned in a 1:1 ratio to either the observation follow-up group (experimental group) or the osimertinib adjuvant treatment group (control group). The aim is to explore whether observation follow-up for patients with negative ctDNA after surgery has a prognosis non-inferior to osimertinib treatment, and to investigate the disease-free survival rate of EGFR mutation-positive stage II-IIIA (N1-N2) NSCLC patients with positive ctDNA after surgery receiving osimertinib adjuvant treatment, providing more precise treatment guidance for adjuvant therapy in this specific type of NSCLC patients with EGFR mutation-positive tumors.

NCT ID: NCT06323239 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.

NCT ID: NCT06323252 Not yet recruiting - Clinical trials for Hypertriglyceridemia

A Study on the Effects of Mastiha Oil in Adults With Hypertriglyceridemia

Start date: April 1, 2024
Phase: N/A
Study type: Interventional

Mastiha Oil is a 100% natural product of the Mediterranean, extracted from the resin of Mastiha. Its composition is high in bioactive ingredients (such as terpenic acids and polyphenols) which have proven anti-inflammatory, antioxidant, cardioprotective, chemoprotective and antimicrobial properties. The aim of this study is to determine the effect of Mastiha oil in adults with Hypetriglyceridemia. 100 participants will be allocated to two groups, (50 in intervention group and 50 in control group). Mastiha oil will be provided in the form of soft gel capsules to the intervention group, whereas the control group will not consume the capsules. Both groups will receive standard nutritional counselling. The intervention will last 3 months. The effects of the intervention will be evaluated via clinical and laboratory markers.